Tanja Obradovic: In order to achieve true breakthroughs in cancer therapy strong science needs to be accompanied with “thinking outside of the box”
Tanja Obradovic shared a post on LinkedIn:
“As with everything road to successful drug development in clinical oncology is informed by past experiences. Remembering time before today of medical oncology in the US, ASCO post article by Vincent DeVita and George Canellos shares some fascinating history and very useful lessons.
It is somewhat hard to believe that very short time ago even combination therapy testing was not something acceptable. Wonderful and truly enlightening read by outstanding experts in the field.
From my personal experience of era before immunotherapy and challenges to establish research into immune system influence upon cancer believe that in order to achieve true breakthroughs in cancer therapy strong science needs to be accompanied with dedication to “thinking outside of the box”.
Source: Tanja Obradovic/LinkedIn
Tanja Obradovic is the Vice President of Oncology Scientific Affairs at ICON PLCh. She has over 20 years of clinical research experience and has led major pharmaceutical companies for 13 years. Her research focuses on small molecules, antibodies, cell and gene therapy, and major immunotherapy of PD1 inhibitors.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023